Having fewer very fine blood vessels in the fold of skin at the base of the fingernails appears to be linked to an increased risk of clinical worsening in pulmonary arterial hypertension (PAH), a study in the Netherlands suggests. People with chronic thromboembolic pulmonary hypertension (CTEPH) also had…
The Pulmonary Hypertension Association (PHA) will host two events the last weekend of October to raise awareness about pulmonary hypertension (PH), seek funding, and support the PH community in anticipation of PH Awareness Month, which happens every…
Treatment with mosliciguat, an inhaled medication given once-daily for pulmonary hypertension (PH), can safely reduce the resistance against blood flow in blood vessels of the lungs, according to a Phase 1 clinical trial. This reduction in pulmonary vascular resistance (PVR) is one of the highest seen in PH…
Tyvaso (inhaled treprostinil) appears to be well tolerated by patients with different types of pulmonary hypertension (PH), and stopping the treatment increases the risk of disease worsening, a study found. The study, “Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil,”…
Ten members of the pulmonary hypertension (PH) community were honored by the Pulmonary Hypertension Association (PHA) for their dedication and service. The Outstanding Member Awards ceremony took place Aug. 17 at the PHA 2024 International PH Conference and Scientific Sessions in Indianapolis. The awards honor people who’ve shown exceptional dedication…
Health Canada has approved Merck’s Winrevair (sotatercept-csrk) for adults with pulmonary arterial hypertension (PAH). The approval specifically covers the use of Winrevair in combination with standard therapies to treat patients with World Health Organization (WHO) functional classification 2 or 3. The decision follows approvals in the U.S., as…
The European Commission has granted orphan medicinal product designation to Cereno Scientific’s CS1 for the treatment of people with pulmonary arterial hypertension (PAH). This designation is given to medications for life-threatening or chronically debilitating diseases, affecting up to five per 10,000 individuals in the European Union (EU), or…
Liquidia is suing the U.S. Food and Drug Administration (FDA) to challenge a decision that delays the final approval of Yutrepia, its inhaled dry-powder formulation of treprostinil, arguing that the delay unfairly limits patient access to important treatment. Yutrepia was granted tentative approval in 2021 to improve the…
Winrevair (sotatercept-csrk), Merck’s injection therapy for adults with pulmonary arterial hypertension (PAH), has been approved in the European Union, as well as in Iceland, Liechtenstein, and Norway. The approval from the European Commission specifically covers Winrevair when used in combination with other PAH therapies to improve…
Airplane travel appears to be safe for people with pulmonary hypertension (PH) with both slight and marked limitations of physical activity, though some individuals may need oxygen support on board to help with breathing, according to a new study. While some patients in the study, dubbed PEGASUS (NCT03051763),…
The protein asporin was identified as a possible biomarker of disease severity and to be protective in pulmonary arterial hypertension (PAH), a study suggests that used lung and blood samples from people with the disease. The protein was increased in PAH patients and correlated with reduced disease severity. In…
The U.S. Food and Drug Administration (FDA) has extended its tentative approval of Yutrepia, an inhaled dry powder formulation of treprostinil, to pulmonary hypertension associated with interstitial lung disease (PH-ILD), a condition that causes the lungs to become scarred. Liquidia’s Yutrepia was granted tentative approval in 2021…
Get regular updates to your inbox.